Publicaciones en colaboración con investigadores/as de Charité (49)

2024

  1. Consensus on the definitions and descriptions of the domains of the OMERACT Core Outcome Set for shared decision making interventions in rheumatology trials

    Seminars in Arthritis and Rheumatism, Vol. 65

  2. OMERACT Core outcome measurement set for shared decision making in rheumatic and musculoskeletal conditions: a scoping review to identify candidate instruments

    Seminars in Arthritis and Rheumatism, Vol. 65

2023

  1. A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis

    Arthritis Research and Therapy, Vol. 25, Núm. 1

  2. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries

    Annals of the rheumatic diseases, Vol. 82, Núm. 5, pp. 698-709

  3. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update

    Annals of the Rheumatic Diseases

  4. High-content multimodal analysis supports the IL-7/IL-7 receptor axis as a relevant therapeutic target in primary Sjögren's syndrome

    Journal of Autoimmunity

2022

  1. After JAK inhibitor failure: To cycle or to switch, that is the question - Data from the JAK-pot collaboration of registries

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 2, pp. 175-181

  2. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

  3. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration

    Annals of the Rheumatic Diseases, Vol. 81, Núm. 10, pp. 1358-1366

  4. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry

    Annals of the rheumatic diseases, Vol. 81, Núm. 5, pp. 695-709

  5. Treat-To-Target in rheumatoid arthritis: A real-world study of the application and impact of treat-To-Target within the wider context of patient management, patient centricity and advanced therapy use in Europe

    RMD Open, Vol. 8, Núm. 2

2021

  1. Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach

    Seminars in Arthritis and Rheumatism, Vol. 51, Núm. 3, pp. 593-600

  2. European League against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance

    Annals of the Rheumatic Diseases, Vol. 80, Núm. 6, pp. 775-781

  3. Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases

    Arthritis and Rheumatology, Vol. 73, Núm. 6, pp. 1073-1085

2020

  1. A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease

    Scientific Reports, Vol. 10, Núm. 1

  2. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 7, pp. 851-858

  3. EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 11, pp. 1423-1431

  4. Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 10, pp. 1333-1339

2019

  1. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 9, pp. 1151-1159

  2. EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases

    RMD Open, Vol. 5, Núm. 2